With buyout of MyoKardia, Bristol-Myers Squibb reaches into heart of Bay Area biotech
October 05, 2020 at 18:02 PM EDT
The potential $13.1 billion deal could accelerate BMS's cardiology portfolio, just like its acquisition of another Bay Area 11 years ago did in cancer.
